Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pfizer decided to discontinue additional enrollment into the study effective Sept 5 2010 after assessing the feasibility of completing this study in a realistic timeframe.The study was not stopped for any safety concerns.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must have a malignant, solid tumor that has been diagnosed as having metastasized to bone, and must have moderate to severe pain secondary to the bone metastasis at an identifiable reference site.
You may not be if
The patient who has undergone diagnostic or therapeutic invasive interventions (angiography, biopsy, surgery) less than 15 days prior to study start that would impact their assessment of pain at the reference pain site or area, in the opinion of the investigator.
